Research aims to optimize brain’s defense mechanisms to combat TBI
By Jan Jarvis
An estimated 1.7 million people in the United States experience loss of cognitive and sensorimotor functions following TBI annually. Those who survive the initial injury often cope with enormous losses in productivity, independence and quality of life.
Researchers at UNT Health Science Center, in collaboration with Epigen Biosciences Inc., a pharmaceutical company in San Diego, are exploring a family of novel compounds that could change how these injuries are treated. This Phase I study is funded by a $417,000 grant from the National Institutes of Health.
The path to clinically effective solutions for TBI is riddled with bumps and puddles, said Victor Uteshev, PhD, Associate Professor of Pharmacology & Neuroscience. TBI presents a considerable intellectual challenge because it is such a complex personal disorder. The concept of individualized medicine is highly relevant to TBI.
“Rephrasing Leo Tolstoy: Healthy brains are all alike, but every traumatically injured brain is unhealthy in its own way,” Dr. Uteshev said. “As a result, development of standardized treatments suitable for all or even many traumatically injured brains is a tremendous challenge. But solving scientific challenges is our job, not inconvenience.”
Despite multiple failures of other approaches in the treatment of TBI, Dr. Uteshev remains optimistic about his novel approach “because we have a powerful ally – nature. The human brain has an intrinsic ability to defend itself from injuries. The defense mechanisms that we study employ the Alpha-7 nicotinic receptors that are very common.”
A balanced activation of Alpha-7 receptors is beneficial for human health. Whenever a brain injury occurs, two simultaneous processes are automatically initiated as the injury stimulates Alpha-7 receptors. First, the brain tissue near the site of injury becomes protected from spreading injury. Then the injury-induced inflammation is mitigated to prevent additional injury.
What Dr. Uteshev proposes is to optimize these two processes by a single class of drugs called positive allosteric modulators of Alpha-7 receptors.
“These drugs may help achieves a healthy balance by modulating natural activation of Alpha-7 receptors after TBI,” he said. “We believe that our novel approach may eventually allow clinicians to optimize the hardwired natural defense mechanisms that are already pre-installed.”
By Alex Branch A UNT Health Science Center graduate won a national leadership award for creating an educational web resource to help patients who are considering a home birth. Chandler Sparks, DO, MPH, a 2018 graduate of the Texas College of Osteopathic Medicine and a Rural Scholar, ...Read more
Oct 15, 2018
By Sally Crocker Dr. Teresa Wagner’s own experiences as a mother trying to help her daughters through two life-threatening health scares, misdiagnosis and providers’ failure to recognize critical symptoms ignited her passion to lead the charge for improved patient health literacy and better c...Read more
Oct 11, 2018
By Jan Jarvis Whether it’s a feline friend or a gregarious goat, pets play a unique role in people’s lives – including those who work at UNT Health Science Center. Here we feature people from across campus, and the pets that light up their lives. J.D. the bull; Egeenee Daniel...Read more
Oct 10, 2018
By Jan Jarvis Ocular inflammation uveitis is a serious disease that can destroy eye tissue and cause irreversible blindness. Fortunately, blindness and eye damage can be prevented by suppressing the immune system and treating the disease with corticosteroids, said Sai Chavala, MD, Pr...Read more
Oct 9, 2018